Boston-based Beta Bionics said this week that it closed a $63 million Series B round to support the development of its iLet bionic pancreas system for people with Type 1 diabetes.
The company’s iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, the algorithms calculate and dose insulin and/or glucagon as needed.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.